(+/-)-3--propionsaeure | 40500-07-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: (+/-)-3--propionsaeure
• 英文别名: 3-(tetrahydro-2H-pyran-2-yl)propionic acid；3-(Oxan-2-yl)propanoic acid
• CAS: 40500-07-0
• 化学式: C₈H₁₄O₃
• mdl: MFCD18483268
• 分子量: 158.197
• InChiKey: QQROKZJSXZUIIB-UHFFFAOYSA-N

物化性质

• 熔点：
  20 °C
• 沸点：
  157 °C(Press: 15 Torr)
• 密度：
  1.087 g/cm3(Temp: 25 °C)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.875
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (+/-)-3--propionsaeure 在 C₂₄H₃₂FeN₆⁽²⁺⁾*2F₆Sb^(1-) 、 双氧水 作用下， 以 水 、 乙腈 为溶剂， 反应 0.35h， 以58%的产率得到1,6-dioxaspiro[4.5]decan-2-one
  参考文献：
  名称：

  Directed Metal (Oxo) Aliphatic C–H Hydroxylations: Overriding Substrate Bias

  摘要：

  The first general strategy for a directing effect on metal (oxo)-promoted C-H hydroxylations is described. Carboxylic acid moieties on the substrate overcome unfavorable electronic, steric, and stereoelectronic biases in C-H hydroxylations catalyzed by the non-heme iron complex Fe(PDP). In a demonstration of the power of this directing effect, C-H oxidation is diverted away from an electronically favored C-1 H abstraction/rearrangement pathway in the paclitaxel framework to enable installation of C-2 oxidation in the naturally occurring oxidation state and stereoconfiguration.

  DOI：

  10.1021/ja301685r
• 作为产物：
  描述：

  四氢吡喃-2-甲醇 在 草酰氯 、 palladium 10% on activated carbon 、 氢气 、 二甲基亚砜 作用下， 以 二氯甲烷 、 异丙醇 为溶剂， 反应 64.17h， 生成 (+/-)-3--propionsaeure
  参考文献：
  名称：

  Directed Metal (Oxo) Aliphatic C–H Hydroxylations: Overriding Substrate Bias

  摘要：

  The first general strategy for a directing effect on metal (oxo)-promoted C-H hydroxylations is described. Carboxylic acid moieties on the substrate overcome unfavorable electronic, steric, and stereoelectronic biases in C-H hydroxylations catalyzed by the non-heme iron complex Fe(PDP). In a demonstration of the power of this directing effect, C-H oxidation is diverted away from an electronically favored C-1 H abstraction/rearrangement pathway in the paclitaxel framework to enable installation of C-2 oxidation in the naturally occurring oxidation state and stereoconfiguration.

  DOI：

  10.1021/ja301685r

文献信息

• New 4-arylpiperidine derivatives for the treatment of pruritus
  申请人：——

  公开号：US20030004340A1

  公开（公告）日：2003-01-02

  There is provided a compound of formula I, 1 wherein Het 1 , R 1 , R 2 , R 3 , X and n have meanings given in the description, which are useful in the prophylaxis and in the treatment of diseases mediated by opiate receptors, such as pruritus.

  提供了一种公式I的化合物，其中Het1、R1、R2、R3、X和n具有说明书中给出的含义，它们在通过阿片受体介导的疾病的预防和治疗中是有用的，例如瘙痒。
• Novel 4-phenylpiperidines for the treatment of pruritic dermatoses
  申请人：——

  公开号：US20030078282A1

  公开（公告）日：2003-04-24

  Novel compounds having general formula (I), and pharmaceutically and veterinarily acceptable salts thereof wherein R 1, R 2, R 3, W, Y 1, Y 2, X, n and y are as defined above and processes for their preparation and intermediate compounds prepared therein. The novel compounds are useful for having utility in the treatment. of pruritic dermatoses including allergic dermatitis and atopy in animals and humans

  具有通用公式(I)的新化合物，以及药物和兽药可接受的盐，其中R 1、R 2、R 3、W、Y 1、Y 2、X、n和y如上所述定义，以及它们的制备过程和其中制备的中间化合物。这些新化合物在治疗包括动物和人类的瘙痒性皮肤病，包括过敏性皮炎和异位症方面具有用途。
• Compounds useful in therapy
  申请人：Pfizer Inc.

  公开号：US20020099214A1

  公开（公告）日：2002-07-25

  There is provided a compound of formula I, 1 wherein R 1 , R 2 , R 3 and Y have meanings given in the description, which are useful in the prophylaxis and in the treatment of pruritus.

  提供了一个式I的化合物， 其中R1、R2、R3和Y的含义如描述中所示，在瘙痒的预防和治疗中有用。
• 4-arylpiperidine derivatives for the treatment of pruritus
  申请人：PFIZER INC.

  公开号：EP1072594A3

  公开（公告）日：2001-02-14

  There is provided a compound of formula I, wherein R1, R2, R3 and Y have meanings given in the description, which are useful in the prophylaxis and in the treatment of pruritus.

  提供了一个化合物，其化学式为I，其中R1、R2、R3和Y的含义如描述中所示，在瘙痒的预防和治疗中很有用。
• [EN] SUBSTITUTED OXOPYRIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXOPYRIDINE SUBSTITUÉS
  申请人：BAYER AG

  公开号：WO2020127504A1

  公开（公告）日：2020-06-25

  The invention relates to substituted oxopyridine derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.

  这项发明涉及替代氧吡啶衍生物及其制备方法，以及它们用于制备药物治疗和/或预防疾病，特别是血管疾病，最好是血栓性或血栓栓塞性疾病和/或血栓性或血栓栓塞性并发症。